Table 4.
Proportion of Migraine Patients Using Prophylactic Medication; Individual Drugs, 3-Year Recall Period
| Substance |
Prevalence Approach (N=14,030) |
Incidence Approach (N=3049) |
||
| n | % | n | % | |
| No Medication | 8584 | 61.2 | 2651 | 86.9 |
| Metoprolol | 1342 | 9.6 | 60 | 2.0 |
| Atenolol | 138 | 0.9 | 5 | 0.2 |
| Bisoprolol | 868 | 6.2 | 44 | 1.4 |
| Candesartan | 115 | 0.8 | 6 | 0.2 |
| Botulinum Toxin A | 49 | 0.4 | 4 | 0.1 |
| Valproic Acid | 826 | 5.9 | 58 | 1.9 |
| Topiramate | 1421 | 10.1 | 96 | 3.2 |
| Gabapentin | 939 | 6.7 | 61 | 2.0 |
| Pregabalin | 791 | 5.6 | 68 | 2.2 |
| Amitriptyline | 341 | 2.4 | 28 | 0.9 |
| Venlafaxine | 722 | 5.2 | 40 | 1.3 |
Abbreviations: n, number of migraine patients with the corresponding prophylactic medication prescribed in 2016; N, total number of migraine patients in 2016; %, percentage of migraine patients with the corresponding prophylactic medication out of the overall number of migraine patients in 2016 with respect to the analysis approach and by the analysis population.